AstraZeneca’s Imfinzi breaks decade Long Drought in Cholangiocarcinoma
IMFINZI® will serve as a first-line treatment for locally advanced or metastatic cholangiocarcinoma in combination with chemotherapy (Gem/Cis).
Transforming Cancer Perceptions: The Power of Objectivity
Putting Cancer in Its Rightful Place — A Journey Toward Empowered Patienthood
Exploring HIPEC Surgery: A Potential Ally in Abdominal Cancer Battles
Discover HIPEC Surgery, an innovative treatment for abdominal cancers. Learn how it works, its benefits, and who can benefit from it.
Clarifying: What is the Checkpoint Pathway?
It is the Successful Handshake that that Occurs between 'PD-1' - the T-Cells Checkpoint Police Officer and 'PD-L1' The Healthy Cells Good Citizen Pass.
The Battle for the Checkpoint Pathway
Which one is best Duvalumab or the new entrant Keytruda? or perhaps this is a tandem opportunity for us patients?
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
Explore the differences in cancer treatments using Gem/Cis with Durvalumab versus Keytruda, focusing on innovative immunotherapy strategies for patient empowerment.
Merck’s Keytruda: A New Hope in Biliary Tract Cancer
Merck's Keytruda gains FDA approval for biliary tract cancer, promising extended survival, rivaling AstraZeneca’s Imfinzi.
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
PBAC endorses IMFINZI (durvalumab) for advanced biliary tract cancer in Australia. First new treatment in 10+ years, boosting survival rates.
Testimonials
CCF Australia is a professional 'Patient-Centric' and 'Patient-Led' Organisation, [...]
Steven West: Cholangio Survivor
The opportunity to help other newly diagnosed patients help themselves, to understand in a manner that they can mount a robust and effective response is the reward
Karen O’Hagan-Humphries: Cholangio Survivor
Surviving Cholangiocarcinoma with HOPE - Discover Steve Holmes and the CCF Australia's patient empowerment tools and initiatives
Lynette Williams: Cholangio Survivor
In order to successfully fight this disease we need to be armed with as much information as possible.
Lisa Salem-Craine: Cholangio Survivor
I met Steve and Claire Holmes many years ago and connected with them because like Steve, I am a cholangiocarcinoma survivor.
Lisa Craine
Beating Cholangiocarcinoma, a bile duct cancer. After several resections and lot of determined research Lisa prevailed
Melinda Bachini
Surviving Cholangiocarcinoma a bile duct cancer is a significant challenge within the cancer world. Melinda Bachini took it on with an amazing supporter community underpinned by willingness and persistence.
Second Opinions Save lives
Second Opinions are a critical factor in surviving Cholangiocarcinoma a bile duct cancer, it an mean the difference between life and death
Andrea Sheardown
Taking on challenges creates a positive environment and positive is what works for Andrea
Intrahepatic Cholangiocarcinoma – Diagnosis and Treatment
Fralin Biomedical Research Institute Timothy Pawlik, M.D., Ph.D. dives deep into discovering and treating intrahepatic cholangiocarcinoma
World Cholangiocarcinoma Day
Contribution and Sharing are powerful human elements in the cancer cure equation - this is my contribution.
Treat the Immune not the Cancer
A breakthrough by Dr Jim Allison Nobel Prize winner - we look into the Ipi /Nivo treatment, a two pronged attack on reactivating the T-Cell
What are Biomarkers
Biomarkers may be used to better understand some of the characteristics of your cancer. Getting tested for biomarkers helps your doctor decide what options are right for you.
PD-1 / PD-L1 is the Checkpoint Pathway
Learn how simple the PD-1 / PD-L1 Pathway is to understand - 4 short videos from easy to technical
A future look into Immuno-Oncology
what a line up! 2018 Nobel Prize winner James P. Allison, Philip D. Greenberg, M.D and Robert H. Vonderheide, Ph.D., and a fireside chat featured insights and opinions from Bristol-Myers Squibb's Vice President, Head of U.S. Oncology
1DH1 and TIBSOVO® (ivosidenib)
Phase 3 trial sees significant benefit as end point is achieved - The company plans to submit a supplemental new drug application for TIBSOVO® in previously treated IDH1 mutant cholangiocarcinoma by the end of 2019.
Blood Biopsies increasing MSI-high detection
A barrier to improved outcomes for many patients is the awareness and testing of MSI status
Ariella Chivil, Cancer Patient success – immunotherapy
Ariella Chivil, an Immunotherapy Advocate, shares her story of self-advocacy and resilience as a young survivor of Hodgkin lymphoma at the 2019 CRI Immunotherapy Summit in Boston.
Cholangiocarcinoma beyond the Blockade
Breakthroughs, Options and Opportunities opening up beyond the Check point inhibitor - beyond PD-1 and the T Cell
Mandy Wallace – NED Cholangiocarcinoma Patient
NED 7.5 years - I woke up on the morning of my 39th birthday with severe pain in my upper abdomen. By lunchtime I had to canceled my birthday party and went to hospital Emergency Department instead. The hospital concluded that I had gallbladder issues, so an ultrasound was scheduled and was sent home with given painkillers to await an ultrasound.
Cholangiocarcinoma and FGFR2
FGF and FGFR2 is a signalling pathway - Fibroblast growth factor signalling uses a fibroblast growth factor receptor (FGFR2) ligand during cell cycle and cell division. The ligand embeds itself into the cell membrane to recieve and deliver growth factors into the cell.
Gem/Cis gets nab-paclitaxel
So, knowing I had no clinical trials for them motivated me to try to write one and think of one that would be something anyone sitting in my clinical could be considered for because that’s what they need.
Scanxiety a new challenge and a special thank you
A Contradiction - It has been what seems like a very long, difficult and unusual battle / journey and with contradictions aside has passed in the blink of an eye.
Steve Holmes – Patient
A terminal diagnosis, that led to significant surgeries, treatments that failed, and then to a modern-day medical breakthrough in cancer
CCA Patient Toolkit
Step-by-step guide & toolkit for bile-duct cancer patients and caregivers, a road map that shines a light on the best pathway ahead
Cholangiocarcinoma Network
Cholangiocarcinoma Australasia Support Network World Wide - Reaching for a Cure
The Luckiest Unlucky Guy – The Matt Reidy Story
The Matt Reidy story serves as a beacon for many. As each of us face off, endure or battle the oppressive CC Beast, we seek out the best pathway back to normality. Matt's story is different from many but he found his way back to his family and a new normality.
Immuno 101
An extract collection of material and articles that relate to Cholangiocarcinoma
Susan Randolph Braden’s Can Sir Production
March 2019 has come roaring in like a lion, and like a Mama lioness, I have been aggressively battling my cancer predator this month.
CCA Introduction pack
Cancer breakthrough -The Globally connected patient and caregiver knowledge, experiences and wisdoms - a collective the equips and empowers
Steve and Claire at the 2019 Cholangiocarcinoma Foundation Annual Conference
Steve and Claire at the 2019 Cholangiocarcinoma Foundation Annual Conference [...]
Genomic Testing – Know your mutations
Molecular Testing Know your Mutations , Information is powerful it improves outcomes
MSI Predictive Biomarkers GI
Experts John L. Marshall, MD, and Alan Venook, MD, comment on the evolution of testing for microsatellite instability (MSI) and tumor mutation burden (TMB
Maria
Maria Shearer shares her story with Cholangiocarcinoma and founding The Cholangiocarcinoma Awareness Facebook Group Community. A Caregivers Story with a twist. Maria Shearer has endured and she has made a difference, she stepped out and up to help others.
Dr Charles Drake explains about Exhausted T Cells
Dr Charles Drake explains about Exhausted T Cells in immunotherapies [...]
Michael Lax sought a second opinion
Michael Lax sought a second opinion on Cholangiocarcinoma at UCSF [...]
Melinda Bachini’s Cholangiocarcinoma Patient Perspective
Melinda Bachini's Cholangiocarcinoma Patient Perspective on Adoptive Cell Therapy,
Treatment options improving for Cholangiocarcinoma
Treatment options improving for Cholangiocarcinoma with Kate Kelly encouraging clinicians to perform tumor profiling
The Immuno sliver bullet; is Immunotherapy a “silver bullet” or is it hype?
The Immuno sliver bullet; is Immunotherapy a “silver bullet” or [...]
Bile Ducts made easy – bile ducts, liver, stomach, pancreas, duodenum
Bile Ducts made easy - An easy to follow video on the relationship between the bile ducts, liver, stomach, pancreas, duodenum and more such as Ampular, Hepatic Artery . . .
Chemotherapy and Cholangiocarcinoma
Chemotherapy and Cholangiocarcinoma - The future direction of Chemotherapy in [...]
As a Cholangiocarcinoma patient living in Australia
As a Cholangiocarcinoma patient living [...]
Cholangio Immuno Warrior strikes another blow on “Cholangio the Beast”
Hi everybody! I think its time for an update because I feel so many of you need some hope. More than ever. I have noticed there are fewer positive news in the last months.
Cholangiocarcinoma – Keytruda as a first line treatment option ?
Cholangiocarcinoma - Keytruda as a first line treatment option ? [...]
Treatment of Intrahepatic Cholangiocarcinoma: A Disease on the Rise
Cholangiocarcinoma - Treatment of Intrahepatic Cholangiocarcinoma: A Disease on the [...]
Surgery for Bile Duct Cancer
Surgery for Bile Duct Cancer, There are 2 general types [...]
Investigating the Biliary RFA Procedure
Investigating the Biliary RFA Procedure for Extrahepatic Cholangiocarinoma Information improves [...]
Sarah Bennett & Linda Fleischer
Cholangiocarcinoma Warrior founder Sarah Bennett and her mother Linda Fleischer [...]
Cholangiocarcinoma – About and Options by Mayo Clinic
Cholangiocarcinoma - Sumera H. Rizvi, MBBS. Gastroenterology fellow at Mayo [...]
Katie Barker, University of Utah 2018, Cholangiocarcinoma and Nutrition
Cholangiocarcinoma and Nutrition and Gastro Intestinal Cancers information that needs [...]
Cholangiocarcinoma Treatment lmproving
THE INCIDENCE of cholangiocarcinoma is rising, and effective therapies are [...]
Adrienne Skinner Cholangiocarcinoma and Keytruda
Adrienne Skinner: Living Life to [...]
Keytruda works on Cholangiocarcinoma Patient
Keytruda works on Cholangiocarcinoma Patient. Adrienne Skinner of Larchmont, [...]
Keytruda may be a miracle cancer drug
Keytruda may be a miracle cancer drug but big questions are being asked about affordability to the people who need it most
Vyriad Expands Phase 1 Trial to Test Voyager-V1
Vyriad is expanding its ongoing Phase 1 clinical trial [...]
Rare Cancers Australia 33 Million Win
The Turnbull Government will provide $33 million to our world [...]
Cycling in the Chemo
Cancer hospital getting chemo patients on bikes to [...]
Bile Duct Cancer – How it develops and how to prevent it
Information improves our Outcomes What do you think about [...]
Capecitabine Improves Survival of Patients with Rare Cancer by Almost a Quarter
Information improves our Outcomes What do you think about [...]
CC with Andrew Clacher
“Having a cancer and no one knowing what it is, or what your fate’s going to be, or even if you’re going to be here in the next two years – it really makes you think about your mortality.”
Elishka’s Story
Choliangiocarcinoma: miss Cholangio was diagnosed in Oct 2015, after I had symptoms of menopause, it was already 7cm x 8cm in the liver, and wrapped around all three major blood vessels, so no surgery for me
Immunotherapy achieves dramatic results
Why does immunotherapy achieve dramatic results in some cancer patients but doesn’t help others? It is an urgent and vexing question for many cancer specialists.
Can Bile Duct Cancer’s follow the Melanoma lead
Patients with metastatic melanoma who are treated with pembrolizumab and achieve a complete response (CR) can maintain those responses for an extended period, even after discontinuation of the therapy, according to a new study.
Bayer enters the immunotherapy race
Bayer joins in . . .Loxo is trying to repeat the trick achieved by Merck & Co (known as MSD outside the US and Canada) when it secured approval for PD1 inhibitor Keytruda (pembrolizumab) for all cancers, regardless of location in the body
AstraZeneca’s Imfinzi breaks decade Long Drought in Cholangiocarcinoma
IMFINZI® will serve as a first-line treatment for locally advanced or metastatic cholangiocarcinoma in combination with chemotherapy (Gem/Cis).
Transforming Cancer Perceptions: The Power of Objectivity
Putting Cancer in Its Rightful Place — A Journey Toward Empowered Patienthood
Exploring HIPEC Surgery: A Potential Ally in Abdominal Cancer Battles
Discover HIPEC Surgery, an innovative treatment for abdominal cancers. Learn how it works, its benefits, and who can benefit from it.
Clarifying: What is the Checkpoint Pathway?
It is the Successful Handshake that that Occurs between 'PD-1' - the T-Cells Checkpoint Police Officer and 'PD-L1' The Healthy Cells Good Citizen Pass.
The Battle for the Checkpoint Pathway
Which one is best Duvalumab or the new entrant Keytruda? or perhaps this is a tandem opportunity for us patients?
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
Explore the differences in cancer treatments using Gem/Cis with Durvalumab versus Keytruda, focusing on innovative immunotherapy strategies for patient empowerment.
Merck’s Keytruda: A New Hope in Biliary Tract Cancer
Merck's Keytruda gains FDA approval for biliary tract cancer, promising extended survival, rivaling AstraZeneca’s Imfinzi.
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
PBAC endorses IMFINZI (durvalumab) for advanced biliary tract cancer in Australia. First new treatment in 10+ years, boosting survival rates.
Testimonials
CCF Australia is a professional 'Patient-Centric' and 'Patient-Led' Organisation, [...]
Steven West: Cholangio Survivor
The opportunity to help other newly diagnosed patients help themselves, to understand in a manner that they can mount a robust and effective response is the reward
Karen O’Hagan-Humphries: Cholangio Survivor
Surviving Cholangiocarcinoma with HOPE - Discover Steve Holmes and the CCF Australia's patient empowerment tools and initiatives
Lynette Williams: Cholangio Survivor
In order to successfully fight this disease we need to be armed with as much information as possible.
Lisa Salem-Craine: Cholangio Survivor
I met Steve and Claire Holmes many years ago and connected with them because like Steve, I am a cholangiocarcinoma survivor.
Lisa Craine
Beating Cholangiocarcinoma, a bile duct cancer. After several resections and lot of determined research Lisa prevailed
Melinda Bachini
Surviving Cholangiocarcinoma a bile duct cancer is a significant challenge within the cancer world. Melinda Bachini took it on with an amazing supporter community underpinned by willingness and persistence.
Second Opinions Save lives
Second Opinions are a critical factor in surviving Cholangiocarcinoma a bile duct cancer, it an mean the difference between life and death
Andrea Sheardown
Taking on challenges creates a positive environment and positive is what works for Andrea
Intrahepatic Cholangiocarcinoma – Diagnosis and Treatment
Fralin Biomedical Research Institute Timothy Pawlik, M.D., Ph.D. dives deep into discovering and treating intrahepatic cholangiocarcinoma
World Cholangiocarcinoma Day
Contribution and Sharing are powerful human elements in the cancer cure equation - this is my contribution.
Treat the Immune not the Cancer
A breakthrough by Dr Jim Allison Nobel Prize winner - we look into the Ipi /Nivo treatment, a two pronged attack on reactivating the T-Cell
What are Biomarkers
Biomarkers may be used to better understand some of the characteristics of your cancer. Getting tested for biomarkers helps your doctor decide what options are right for you.
PD-1 / PD-L1 is the Checkpoint Pathway
Learn how simple the PD-1 / PD-L1 Pathway is to understand - 4 short videos from easy to technical
A future look into Immuno-Oncology
what a line up! 2018 Nobel Prize winner James P. Allison, Philip D. Greenberg, M.D and Robert H. Vonderheide, Ph.D., and a fireside chat featured insights and opinions from Bristol-Myers Squibb's Vice President, Head of U.S. Oncology
1DH1 and TIBSOVO® (ivosidenib)
Phase 3 trial sees significant benefit as end point is achieved - The company plans to submit a supplemental new drug application for TIBSOVO® in previously treated IDH1 mutant cholangiocarcinoma by the end of 2019.
Blood Biopsies increasing MSI-high detection
A barrier to improved outcomes for many patients is the awareness and testing of MSI status
Ariella Chivil, Cancer Patient success – immunotherapy
Ariella Chivil, an Immunotherapy Advocate, shares her story of self-advocacy and resilience as a young survivor of Hodgkin lymphoma at the 2019 CRI Immunotherapy Summit in Boston.
Cholangiocarcinoma beyond the Blockade
Breakthroughs, Options and Opportunities opening up beyond the Check point inhibitor - beyond PD-1 and the T Cell
Mandy Wallace – NED Cholangiocarcinoma Patient
NED 7.5 years - I woke up on the morning of my 39th birthday with severe pain in my upper abdomen. By lunchtime I had to canceled my birthday party and went to hospital Emergency Department instead. The hospital concluded that I had gallbladder issues, so an ultrasound was scheduled and was sent home with given painkillers to await an ultrasound.
Cholangiocarcinoma and FGFR2
FGF and FGFR2 is a signalling pathway - Fibroblast growth factor signalling uses a fibroblast growth factor receptor (FGFR2) ligand during cell cycle and cell division. The ligand embeds itself into the cell membrane to recieve and deliver growth factors into the cell.
Gem/Cis gets nab-paclitaxel
So, knowing I had no clinical trials for them motivated me to try to write one and think of one that would be something anyone sitting in my clinical could be considered for because that’s what they need.
Scanxiety a new challenge and a special thank you
A Contradiction - It has been what seems like a very long, difficult and unusual battle / journey and with contradictions aside has passed in the blink of an eye.
Steve Holmes – Patient
A terminal diagnosis, that led to significant surgeries, treatments that failed, and then to a modern-day medical breakthrough in cancer
CCA Patient Toolkit
Step-by-step guide & toolkit for bile-duct cancer patients and caregivers, a road map that shines a light on the best pathway ahead
Cholangiocarcinoma Network
Cholangiocarcinoma Australasia Support Network World Wide - Reaching for a Cure
The Luckiest Unlucky Guy – The Matt Reidy Story
The Matt Reidy story serves as a beacon for many. As each of us face off, endure or battle the oppressive CC Beast, we seek out the best pathway back to normality. Matt's story is different from many but he found his way back to his family and a new normality.
Immuno 101
An extract collection of material and articles that relate to Cholangiocarcinoma
Susan Randolph Braden’s Can Sir Production
March 2019 has come roaring in like a lion, and like a Mama lioness, I have been aggressively battling my cancer predator this month.
CCA Introduction pack
Cancer breakthrough -The Globally connected patient and caregiver knowledge, experiences and wisdoms - a collective the equips and empowers
Steve and Claire at the 2019 Cholangiocarcinoma Foundation Annual Conference
Steve and Claire at the 2019 Cholangiocarcinoma Foundation Annual Conference [...]
Genomic Testing – Know your mutations
Molecular Testing Know your Mutations , Information is powerful it improves outcomes
MSI Predictive Biomarkers GI
Experts John L. Marshall, MD, and Alan Venook, MD, comment on the evolution of testing for microsatellite instability (MSI) and tumor mutation burden (TMB
Maria
Maria Shearer shares her story with Cholangiocarcinoma and founding The Cholangiocarcinoma Awareness Facebook Group Community. A Caregivers Story with a twist. Maria Shearer has endured and she has made a difference, she stepped out and up to help others.
Dr Charles Drake explains about Exhausted T Cells
Dr Charles Drake explains about Exhausted T Cells in immunotherapies [...]
Michael Lax sought a second opinion
Michael Lax sought a second opinion on Cholangiocarcinoma at UCSF [...]
Melinda Bachini’s Cholangiocarcinoma Patient Perspective
Melinda Bachini's Cholangiocarcinoma Patient Perspective on Adoptive Cell Therapy,
Treatment options improving for Cholangiocarcinoma
Treatment options improving for Cholangiocarcinoma with Kate Kelly encouraging clinicians to perform tumor profiling
The Immuno sliver bullet; is Immunotherapy a “silver bullet” or is it hype?
The Immuno sliver bullet; is Immunotherapy a “silver bullet” or [...]
Bile Ducts made easy – bile ducts, liver, stomach, pancreas, duodenum
Bile Ducts made easy - An easy to follow video on the relationship between the bile ducts, liver, stomach, pancreas, duodenum and more such as Ampular, Hepatic Artery . . .
Chemotherapy and Cholangiocarcinoma
Chemotherapy and Cholangiocarcinoma - The future direction of Chemotherapy in [...]
As a Cholangiocarcinoma patient living in Australia
As a Cholangiocarcinoma patient living [...]
Cholangio Immuno Warrior strikes another blow on “Cholangio the Beast”
Hi everybody! I think its time for an update because I feel so many of you need some hope. More than ever. I have noticed there are fewer positive news in the last months.
Cholangiocarcinoma – Keytruda as a first line treatment option ?
Cholangiocarcinoma - Keytruda as a first line treatment option ? [...]
Treatment of Intrahepatic Cholangiocarcinoma: A Disease on the Rise
Cholangiocarcinoma - Treatment of Intrahepatic Cholangiocarcinoma: A Disease on the [...]
Surgery for Bile Duct Cancer
Surgery for Bile Duct Cancer, There are 2 general types [...]
Investigating the Biliary RFA Procedure
Investigating the Biliary RFA Procedure for Extrahepatic Cholangiocarinoma Information improves [...]
Sarah Bennett & Linda Fleischer
Cholangiocarcinoma Warrior founder Sarah Bennett and her mother Linda Fleischer [...]
Cholangiocarcinoma – About and Options by Mayo Clinic
Cholangiocarcinoma - Sumera H. Rizvi, MBBS. Gastroenterology fellow at Mayo [...]
Katie Barker, University of Utah 2018, Cholangiocarcinoma and Nutrition
Cholangiocarcinoma and Nutrition and Gastro Intestinal Cancers information that needs [...]
Cholangiocarcinoma Treatment lmproving
THE INCIDENCE of cholangiocarcinoma is rising, and effective therapies are [...]
Adrienne Skinner Cholangiocarcinoma and Keytruda
Adrienne Skinner: Living Life to [...]
Keytruda works on Cholangiocarcinoma Patient
Keytruda works on Cholangiocarcinoma Patient. Adrienne Skinner of Larchmont, [...]
Keytruda may be a miracle cancer drug
Keytruda may be a miracle cancer drug but big questions are being asked about affordability to the people who need it most
Vyriad Expands Phase 1 Trial to Test Voyager-V1
Vyriad is expanding its ongoing Phase 1 clinical trial [...]
Rare Cancers Australia 33 Million Win
The Turnbull Government will provide $33 million to our world [...]
Cycling in the Chemo
Cancer hospital getting chemo patients on bikes to [...]
Bile Duct Cancer – How it develops and how to prevent it
Information improves our Outcomes What do you think about [...]
Capecitabine Improves Survival of Patients with Rare Cancer by Almost a Quarter
Information improves our Outcomes What do you think about [...]
CC with Andrew Clacher
“Having a cancer and no one knowing what it is, or what your fate’s going to be, or even if you’re going to be here in the next two years – it really makes you think about your mortality.”
Elishka’s Story
Choliangiocarcinoma: miss Cholangio was diagnosed in Oct 2015, after I had symptoms of menopause, it was already 7cm x 8cm in the liver, and wrapped around all three major blood vessels, so no surgery for me
Immunotherapy achieves dramatic results
Why does immunotherapy achieve dramatic results in some cancer patients but doesn’t help others? It is an urgent and vexing question for many cancer specialists.
Can Bile Duct Cancer’s follow the Melanoma lead
Patients with metastatic melanoma who are treated with pembrolizumab and achieve a complete response (CR) can maintain those responses for an extended period, even after discontinuation of the therapy, according to a new study.
Bayer enters the immunotherapy race
Bayer joins in . . .Loxo is trying to repeat the trick achieved by Merck & Co (known as MSD outside the US and Canada) when it secured approval for PD1 inhibitor Keytruda (pembrolizumab) for all cancers, regardless of location in the body
AstraZeneca’s Imfinzi breaks decade Long Drought in Cholangiocarcinoma
IMFINZI® will serve as a first-line treatment for locally advanced or metastatic cholangiocarcinoma in combination with chemotherapy (Gem/Cis).
Transforming Cancer Perceptions: The Power of Objectivity
Putting Cancer in Its Rightful Place — A Journey Toward Empowered Patienthood
Exploring HIPEC Surgery: A Potential Ally in Abdominal Cancer Battles
Discover HIPEC Surgery, an innovative treatment for abdominal cancers. Learn how it works, its benefits, and who can benefit from it.
Clarifying: What is the Checkpoint Pathway?
It is the Successful Handshake that that Occurs between 'PD-1' - the T-Cells Checkpoint Police Officer and 'PD-L1' The Healthy Cells Good Citizen Pass.
The Battle for the Checkpoint Pathway
Which one is best Duvalumab or the new entrant Keytruda? or perhaps this is a tandem opportunity for us patients?
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
Explore the differences in cancer treatments using Gem/Cis with Durvalumab versus Keytruda, focusing on innovative immunotherapy strategies for patient empowerment.
Merck’s Keytruda: A New Hope in Biliary Tract Cancer
Merck's Keytruda gains FDA approval for biliary tract cancer, promising extended survival, rivaling AstraZeneca’s Imfinzi.
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
PBAC endorses IMFINZI (durvalumab) for advanced biliary tract cancer in Australia. First new treatment in 10+ years, boosting survival rates.
Testimonials
CCF Australia is a professional 'Patient-Centric' and 'Patient-Led' Organisation, [...]
Steven West: Cholangio Survivor
The opportunity to help other newly diagnosed patients help themselves, to understand in a manner that they can mount a robust and effective response is the reward
Karen O’Hagan-Humphries: Cholangio Survivor
Surviving Cholangiocarcinoma with HOPE - Discover Steve Holmes and the CCF Australia's patient empowerment tools and initiatives
Lynette Williams: Cholangio Survivor
In order to successfully fight this disease we need to be armed with as much information as possible.
Lisa Salem-Craine: Cholangio Survivor
I met Steve and Claire Holmes many years ago and connected with them because like Steve, I am a cholangiocarcinoma survivor.
Lisa Craine
Beating Cholangiocarcinoma, a bile duct cancer. After several resections and lot of determined research Lisa prevailed
Melinda Bachini
Surviving Cholangiocarcinoma a bile duct cancer is a significant challenge within the cancer world. Melinda Bachini took it on with an amazing supporter community underpinned by willingness and persistence.
Second Opinions Save lives
Second Opinions are a critical factor in surviving Cholangiocarcinoma a bile duct cancer, it an mean the difference between life and death
Andrea Sheardown
Taking on challenges creates a positive environment and positive is what works for Andrea
Intrahepatic Cholangiocarcinoma – Diagnosis and Treatment
Fralin Biomedical Research Institute Timothy Pawlik, M.D., Ph.D. dives deep into discovering and treating intrahepatic cholangiocarcinoma
World Cholangiocarcinoma Day
Contribution and Sharing are powerful human elements in the cancer cure equation - this is my contribution.
Treat the Immune not the Cancer
A breakthrough by Dr Jim Allison Nobel Prize winner - we look into the Ipi /Nivo treatment, a two pronged attack on reactivating the T-Cell
What are Biomarkers
Biomarkers may be used to better understand some of the characteristics of your cancer. Getting tested for biomarkers helps your doctor decide what options are right for you.
PD-1 / PD-L1 is the Checkpoint Pathway
Learn how simple the PD-1 / PD-L1 Pathway is to understand - 4 short videos from easy to technical
A future look into Immuno-Oncology
what a line up! 2018 Nobel Prize winner James P. Allison, Philip D. Greenberg, M.D and Robert H. Vonderheide, Ph.D., and a fireside chat featured insights and opinions from Bristol-Myers Squibb's Vice President, Head of U.S. Oncology
1DH1 and TIBSOVO® (ivosidenib)
Phase 3 trial sees significant benefit as end point is achieved - The company plans to submit a supplemental new drug application for TIBSOVO® in previously treated IDH1 mutant cholangiocarcinoma by the end of 2019.
Blood Biopsies increasing MSI-high detection
A barrier to improved outcomes for many patients is the awareness and testing of MSI status
Ariella Chivil, Cancer Patient success – immunotherapy
Ariella Chivil, an Immunotherapy Advocate, shares her story of self-advocacy and resilience as a young survivor of Hodgkin lymphoma at the 2019 CRI Immunotherapy Summit in Boston.
Cholangiocarcinoma beyond the Blockade
Breakthroughs, Options and Opportunities opening up beyond the Check point inhibitor - beyond PD-1 and the T Cell
Mandy Wallace – NED Cholangiocarcinoma Patient
NED 7.5 years - I woke up on the morning of my 39th birthday with severe pain in my upper abdomen. By lunchtime I had to canceled my birthday party and went to hospital Emergency Department instead. The hospital concluded that I had gallbladder issues, so an ultrasound was scheduled and was sent home with given painkillers to await an ultrasound.
Cholangiocarcinoma and FGFR2
FGF and FGFR2 is a signalling pathway - Fibroblast growth factor signalling uses a fibroblast growth factor receptor (FGFR2) ligand during cell cycle and cell division. The ligand embeds itself into the cell membrane to recieve and deliver growth factors into the cell.
Gem/Cis gets nab-paclitaxel
So, knowing I had no clinical trials for them motivated me to try to write one and think of one that would be something anyone sitting in my clinical could be considered for because that’s what they need.
Scanxiety a new challenge and a special thank you
A Contradiction - It has been what seems like a very long, difficult and unusual battle / journey and with contradictions aside has passed in the blink of an eye.
Steve Holmes – Patient
A terminal diagnosis, that led to significant surgeries, treatments that failed, and then to a modern-day medical breakthrough in cancer
CCA Patient Toolkit
Step-by-step guide & toolkit for bile-duct cancer patients and caregivers, a road map that shines a light on the best pathway ahead
Cholangiocarcinoma Network
Cholangiocarcinoma Australasia Support Network World Wide - Reaching for a Cure
The Luckiest Unlucky Guy – The Matt Reidy Story
The Matt Reidy story serves as a beacon for many. As each of us face off, endure or battle the oppressive CC Beast, we seek out the best pathway back to normality. Matt's story is different from many but he found his way back to his family and a new normality.
Immuno 101
An extract collection of material and articles that relate to Cholangiocarcinoma
Susan Randolph Braden’s Can Sir Production
March 2019 has come roaring in like a lion, and like a Mama lioness, I have been aggressively battling my cancer predator this month.
CCA Introduction pack
Cancer breakthrough -The Globally connected patient and caregiver knowledge, experiences and wisdoms - a collective the equips and empowers
Steve and Claire at the 2019 Cholangiocarcinoma Foundation Annual Conference
Steve and Claire at the 2019 Cholangiocarcinoma Foundation Annual Conference [...]
Genomic Testing – Know your mutations
Molecular Testing Know your Mutations , Information is powerful it improves outcomes
MSI Predictive Biomarkers GI
Experts John L. Marshall, MD, and Alan Venook, MD, comment on the evolution of testing for microsatellite instability (MSI) and tumor mutation burden (TMB
Maria
Maria Shearer shares her story with Cholangiocarcinoma and founding The Cholangiocarcinoma Awareness Facebook Group Community. A Caregivers Story with a twist. Maria Shearer has endured and she has made a difference, she stepped out and up to help others.
Dr Charles Drake explains about Exhausted T Cells
Dr Charles Drake explains about Exhausted T Cells in immunotherapies [...]
Michael Lax sought a second opinion
Michael Lax sought a second opinion on Cholangiocarcinoma at UCSF [...]
Melinda Bachini’s Cholangiocarcinoma Patient Perspective
Melinda Bachini's Cholangiocarcinoma Patient Perspective on Adoptive Cell Therapy,
Treatment options improving for Cholangiocarcinoma
Treatment options improving for Cholangiocarcinoma with Kate Kelly encouraging clinicians to perform tumor profiling
The Immuno sliver bullet; is Immunotherapy a “silver bullet” or is it hype?
The Immuno sliver bullet; is Immunotherapy a “silver bullet” or [...]
Bile Ducts made easy – bile ducts, liver, stomach, pancreas, duodenum
Bile Ducts made easy - An easy to follow video on the relationship between the bile ducts, liver, stomach, pancreas, duodenum and more such as Ampular, Hepatic Artery . . .
Chemotherapy and Cholangiocarcinoma
Chemotherapy and Cholangiocarcinoma - The future direction of Chemotherapy in [...]
As a Cholangiocarcinoma patient living in Australia
As a Cholangiocarcinoma patient living [...]
Cholangio Immuno Warrior strikes another blow on “Cholangio the Beast”
Hi everybody! I think its time for an update because I feel so many of you need some hope. More than ever. I have noticed there are fewer positive news in the last months.
Cholangiocarcinoma – Keytruda as a first line treatment option ?
Cholangiocarcinoma - Keytruda as a first line treatment option ? [...]
Treatment of Intrahepatic Cholangiocarcinoma: A Disease on the Rise
Cholangiocarcinoma - Treatment of Intrahepatic Cholangiocarcinoma: A Disease on the [...]
Surgery for Bile Duct Cancer
Surgery for Bile Duct Cancer, There are 2 general types [...]
Investigating the Biliary RFA Procedure
Investigating the Biliary RFA Procedure for Extrahepatic Cholangiocarinoma Information improves [...]
Sarah Bennett & Linda Fleischer
Cholangiocarcinoma Warrior founder Sarah Bennett and her mother Linda Fleischer [...]
Cholangiocarcinoma – About and Options by Mayo Clinic
Cholangiocarcinoma - Sumera H. Rizvi, MBBS. Gastroenterology fellow at Mayo [...]
Katie Barker, University of Utah 2018, Cholangiocarcinoma and Nutrition
Cholangiocarcinoma and Nutrition and Gastro Intestinal Cancers information that needs [...]
Cholangiocarcinoma Treatment lmproving
THE INCIDENCE of cholangiocarcinoma is rising, and effective therapies are [...]
Adrienne Skinner Cholangiocarcinoma and Keytruda
Adrienne Skinner: Living Life to [...]
Keytruda works on Cholangiocarcinoma Patient
Keytruda works on Cholangiocarcinoma Patient. Adrienne Skinner of Larchmont, [...]
Keytruda may be a miracle cancer drug
Keytruda may be a miracle cancer drug but big questions are being asked about affordability to the people who need it most
Vyriad Expands Phase 1 Trial to Test Voyager-V1
Vyriad is expanding its ongoing Phase 1 clinical trial [...]
Rare Cancers Australia 33 Million Win
The Turnbull Government will provide $33 million to our world [...]
Cycling in the Chemo
Cancer hospital getting chemo patients on bikes to [...]
Bile Duct Cancer – How it develops and how to prevent it
Information improves our Outcomes What do you think about [...]
Capecitabine Improves Survival of Patients with Rare Cancer by Almost a Quarter
Information improves our Outcomes What do you think about [...]
CC with Andrew Clacher
“Having a cancer and no one knowing what it is, or what your fate’s going to be, or even if you’re going to be here in the next two years – it really makes you think about your mortality.”
Elishka’s Story
Choliangiocarcinoma: miss Cholangio was diagnosed in Oct 2015, after I had symptoms of menopause, it was already 7cm x 8cm in the liver, and wrapped around all three major blood vessels, so no surgery for me
Immunotherapy achieves dramatic results
Why does immunotherapy achieve dramatic results in some cancer patients but doesn’t help others? It is an urgent and vexing question for many cancer specialists.
Can Bile Duct Cancer’s follow the Melanoma lead
Patients with metastatic melanoma who are treated with pembrolizumab and achieve a complete response (CR) can maintain those responses for an extended period, even after discontinuation of the therapy, according to a new study.
Bayer enters the immunotherapy race
Bayer joins in . . .Loxo is trying to repeat the trick achieved by Merck & Co (known as MSD outside the US and Canada) when it secured approval for PD1 inhibitor Keytruda (pembrolizumab) for all cancers, regardless of location in the body
